間充質(zhì)干細(xì)胞（MSCs）是來源于中胚層的成體干細(xì)胞，體內(nèi)分布廣泛，可從骨髓、脂肪、牙髓、臍帶/胎盤等組織中分離獲取，具有高度的可增殖和分化潛能，較低的免疫原性，同時具有向炎癥損傷部位微環(huán)境的趨向性，在疾病治療方面可作為基因藥物的載體實現(xiàn)精準(zhǔn)治療。癌癥被認(rèn)為是永遠(yuǎn)無法愈合的傷口，其組織微環(huán)境在損傷與修復(fù)中呈無休止的動態(tài)變化，MSCs在其中扮演了重要角色。利用MSCs具有的向腫瘤組織中歸巢及定位的特點，對其進(jìn)行抗腫瘤藥物的基因工程改造可能在癌癥的治療上是一種新的策略。概述MSCs在癌癥發(fā)生發(fā)展中的作用以及基因修飾MSCs治療癌癥的研究進(jìn)展，旨在為臨床使用基因修飾MSCs治療癌癥提供策略和見解。

Mesenchymal stem cells (MSCs) is one of the adult stem cells, which is derived from mesoderm tissues. MSCs are widely distributed in tissues and organs, and can be isolated from bone marrow, fat, dental pulp, umbilical cord/placenta and other tissues. MSCs have high potential for proliferation and differentiation, low immunogenicity and a tendency to the microenvironment of inflammatory injury sites. MSCs hold clinical promise for the treatment of many diseases. Cancer is considered as a wound that can never be healed, and its tissue microenvironment changes endlessly during injury and repair, in which mesenchymal stem cells play an important role. Using the characteristics of mesenchymal stem cells to home and locate tumor tissue, genetic modification of MSCs with antitumor drug may be a new strategy in the treatment of cancer. This paper summarizes the role of mesenchymal stem cells in the occurrence and development of cancer and the research progress of gene modified mesenchymal stem cells in the treatment of cancer, in order to provide strategies and insights for the clinical use of gene modified mesenchymal stem cells in the treatment of cancer.

北京市科技計劃課題（Z211100002521006）